Abstract. Regulator of G protein signaling 5 (RGS5) belongs to the R4 subfamily of RGS proteins, a family of GTPase activating proteins, which is dynamically regulated in various biological processes including blood pressure regulation, smooth muscle cell pathology, fat metabolism and tumor angiogenesis. Low-expression of RGS5 was reported to be associated with tumor progression in lung cancer. In the present study, we examined the potential roles of RGS5 in human lung cancer cells by overexpressing RGS5 in the cancer cells and further explored the underlying molecular mechanisms. The RGS5 gene was cloned and transfected into the human lung cancer cell lines A549 and Calu-3. The cells were tested for apoptosis with flow cytometry, for viability with MTT, for mobility and adhesion capacity. The radiosensitization effect of RGS5 was measured by a colony formation assay. The mechanisms of RGS5 functioning was also investigated by detection of protein expression with western blot analysis, including PARP, caspase 3 and 9, bax, bcl2, Rock1, Rock2, CDC42, phospho-p53 (Serine 15) and p53. The present study demonstrated that RGS5 overexpression remarkably induced apoptosis in human lung cancer cells, which was suggested to be through mitochondrial mechanisms. Overexpression of RGS5 resulted in significantly lower adhesion and migration abilities of the lung cancer cells (P<0.01). Furthermore, overexpression of RGS5 sensitized the lung cancer cells to radiation. In conclusion, the present study showed that RGS5 played an inhibitory role in human lung cancer cells through induction of apoptosis. Furthermore, RGS5 enhanced the cytotoxic effect of radiation in the human lung cancer cells. Our results indicated that RGS5 may be a potential target for cancer therapy.
Introduction
Regulator of G protein signaling (RGS) proteins is a family of GTPase activating proteins, which interact directly with α subunit of heterotrimeric G proteins to accelerate the GTP hydrolysis activity of the α subunit and negatively regulate the G protein signaling (1, 2) . All the RGS family members contain an essential 120-amino acid RGS domain. Regulator of G protein signaling 5 (RGS5) belongs to the R4 subfamily of RGS proteins, which consists mostly of small RGS proteins containing only short sequences beyond the RGS domain (3) . RGS5 expression is abundant in pericytes and vascular smooth muscle cells (4, 5) and high levels of RGS5 have been detected in the heart, lung, skeletal muscle and small intestine, while lower levels have been found in the brain, placenta, liver, colon and leukocytes (6) . RGS5 has been implicated in many pathophysiological processes including cardiac hypertrophy (7), blood pressure regulation (8) , atherosclerosis (9, 10) , lipid metabolism (11) , bronchial smooth muscle cell contraction and asthma (12) . RGS5 was markedly downregulated during the endothelial cell morphogenesis in an in vitro human capillary tube formation model (13) . RGS5 levels were elevated in pericytes during wound healing and ovulation, suggesting a strong correlation between the RGS5 expression and the active vessel remodeling (14, 15) .
Substantial evidence indicates an active role of RGS5 in tumor angiogenesis. RGS5 is found highly expressed in the vasculature of several tumors. RGS5 mRNA is expressed in the endothelial cells of tumor vessels, but not in the endothelial cells of the normal tissues in renal cell carcinoma (RCC) (16) , hepatic cell carcinoma (HCC) (17) and ovarian carcinoma (18 (14) . Elevated expression of RGS5 has been reported in tumor cells in gastric tumor (19) , parathyroid (20) and non-small cell lung cancer (NSCLC) (21) . Yet, the fundamental role RGS5 played in the neoplasm and its mechanisms are still to be clarified.
In the present study, we investigated the potential role of the high levels of RGS5 in human lung cancer cells and further explored the underlying molecular mechanisms.
Materials and methods
Ethics statement. The present study conforms to the principles outlined in the Declaration of Helsinki, and was approved by the Medical Ethics Committee of Sun Yat-Sen university. Written informed consents were obtained from the donors.
Cells and cultures.
Human lung cancer cell lines A549, Calu-3, H1299 and SK-MES-1 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS) (both from Life Technologies, Grand Island, NY, USA) at 37˚C, 5% CO 2 in a humidified incubator. Human umbilical vein endothelial cells (HuVECs) were freshly isolated from the human umbilical cord veins, and incubated in the human endothelial-SFM basal growth medium supplemented with 20% fetal calf serum, 100 µg/ml streptomycin, 100 u/ml penicillin, 5 µg/ml amphotericin B (Life Technologies), 2 mmol/l l-glutamine, 15 mg/l ECGS (upstate Biotechnology, Lake Placid, NY, uSA) (22) . mRNA extraction and reverse transcription PCR. mRNA extractions were performed with an ultrapure RNA purification kit (Kangweishiji Biotech Co., Ltd., China) according to the manufacturer instructions. Approximately 500 ng of RNA was reverse transcribed into complementary DNA using a PrimeScript RT Reagent kit (Takara, Shiga, Japan). Relative quantity of RGS5 mRNA was determined using GAPDH as an internal control. PCR was performed with the primers for RGS5, 5'-atgtgcaaaggacttgcagc-3'/5'-ctacttgattaactcctgat-3'; and GAPDH, 5'-tccaccaccctgttgctgta-3'/5'-accacagtccatgc atcac-3'.
Cloning of RGS5 coding region and cell transfection. The complete RGS5 coding region was cloned into the pTRiEX Neo expression vector (Novagen, uSA) for transient transfection of cancer cell lines. The RGS5 coding region was amplified from cDNA of HuVECs using primers 5'-cgcggatccgggatcc gatgtgcaaaggacttgcagc-3' and 5'-ccgctcgagcttgattaactcctgataaa ac-3' which contain restriction site tags for BamHI and XhoI, respectively. The RGS5 coding region was then cloned into the pTRiEX Neo vector (Clontech, uSA). Human lung cancer cell lines A549 and Calu-3 were transiently transfected with pTRiEX vectors or pTRiEX-RGS5 plasmids using Attractene Transfection Reagent (Qiagen, Germany) according to the protocol of the manufacturer.
Cell viability. Cell viability was measured by MTT assays as previously described (23) . At various time-points following transfection, MTT solution was added at a final concentration of 0.5 mg/ml and the cells were incubated for 4 h at 37˚C. Formazan crystals in the viable cells were solubilized with dimethyl sulfoxide and the absorbance was measured at 570 nm.
Colony formation assay. The cells were seeded into 6-well plates at a density of 500 cells/well. For radiation groups, 6-well plates were irradiated with 2 or 6 Gy X-ray 12 h after seeding. Irradiation was performed at room temperature using RS 2000 X-ray Biological Irradiator (Rad Source Technologies, uSA) at a dose rate of 1 Gy/min through a 0.2-mm copper filter. The plates were incubated for 10 days at 37˚C with the growth medium being replaced every 3 days. The colonies were fixed with methanol and stained with 0.5% crystal violet (in methanol:water, 1:1). The number of the colonies containing at least 50 cells was then counted. Data are presented as means ± SE (SEM) of at least three independent experiments.
Apoptosis assay. The cells were collected at 36 h after transfection and the apoptotic cells were analyzed using flow cytometry (FACS) with an Annexin V/propidium iodide (PI)-staining assay according to the instructions of the manufacturer (Kaiji Biotechnology Co., Nanjing, China).
Cell adhesion assay. Ninety-six-well plates were coated with human fibronectin (BD Biosciences) at a final concentration of 2 µg/ml overnight at 4˚C. The plates were washed with 1% bovine serum albumin in phosphate-buffered saline (PBS) to block non-specific cell adhesion. Twelve hours after being transfected with either pTRiEX or pTRiEX-RGS5 plasmids, the cells were trypsinized and seeded at 5x10 4 cells/well, and then incubated for 1 h. The plates were washed with PBS to remove non-adherent cells, fixed with formalin and followed by staining with crystal violet for 15 min and solubilized with 1% SDS. The absorbance was measured at 570 nm by a microplate reader (Tecan Sunrise, Germany). All the experiments were performed in triplicates and repeated at least three times.
Cell migration assay. The in vitro migration ability of the cells was measured using an 8-µm Boyden chamber assay (Corning, uSA). Twelve hours after transfection with pTRiEX or pTRiEX-RGS5 plasmids, the cells were trypsinized and seeded into the upper chamber. A total of 2x10 4 cells in 0.2 ml of 2% FBS medium was placed in the upper chamber, whereas the lower chamber was loaded with 0.8 ml medium containing 20% FBS. After incubation at 37˚C for 12 h, non-migratory cells were wiped off with PBS-rinsed cotton swabs. The filters were then fixed in ethanol, stained with crystal violet. The stained cells were counted under a microscope (Olympus, Tokyo, Japan). Values for migration were expressed as the average number of migrated cells/microscopic field over six fields/assay from three independent experiments.
Western blot analysis. The cells were lysed in lysis buffer [20 mM Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 0.4 mM PMSF] and heated at 100˚C for 10 min. The protein concentration was determined using the Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA, uSA). The samples were separated by SDS-PAGE and transferred to the PVDF membranes (Bio-Rad). The membranes were blocked in 5% milk for 1 h. Protein expression was detected using primary antibodies incubated overnight at 4˚C. The membranes were washed and incubated for 1 h with HRP-conjugated secondary antibodies at room temperature. The following primary antibodies were used: anti-RGS5 (1:1,000), anti-PARP (1:1,000), anti-caspase 3 (1:1,000), anti-caspase 9 (1:1,000), anti-bax (1:2,000), anti-bcl (1:1,000), anti-Rock1 (1:1,000), anti-Rock2 (1:1,000), anti-CDC42 (1:1,000), anti-Phosphop53 (Serine 15) (1:1,000) and anti-p53 (1:1,000). Horseradish peroxidase-coupled anti-rabbit or anti-mouse antibodies (Vector Laboratories) were used at a dilution of 1:1,000. The blots were probed with an anti-β-actin antibody (Sigma) for equal loading.
Statistical analysis. Data are presented as mean ± SEM. Differences of the variables between the groups were analyzed by one-way ANOVA test. Differences were considered significant at P<0.05.
Results

Expression of RGS5 in human lung cancer cells.
Four human non-small cell lung cancer cell lines were tested for the expression levels of RGS5 using RT-PCR and western blot analysis with HuVECs as positive controls. RGS5 was differentially expressed in human lung cancer cells, with high levels in H1299 cells and undetectable levels in A549, Calu-3 and SK-MES-1 cells (Fig. 1) .
Overexpressing of RGS5 in A549 and Calu-3 cells inhibits growth and clongenic survival. As shown in Fig. 2, A549 and Calu-3 cells that were transfected with RGS5-expressing plasmid had markedly increased levels of RGS5 mRNA and protein, compared to the cells transfected with the vector control.
upon transfection with RGS5-expressing plasmid, both A549 and Calu-3 cells showed reduced cell density at 36 h post-transfection, compared to the cells receiving vector control or no plasmid (Fig. 3A ). An MTT assay was employed to study the effects of overexpression of RGS5 on the cell growth. As shown in Fig. 3B , expression of RGS5 was able to significantly inhibit the growth of both A549 and Calu-3 cells. Compared to the cells receiving vector control, growth inhibition of A549 and Calu-3 cells was 44.4 and 39.27% at 48 h, and 54.3, 44.7% at 72 h, respectively (Fig. 3C) . The in vitro clonogenic assay further confirmed that overexpression of RGS5 asserted an inhibitory effect on the cell proliferation. Compared to the non-transfected control or the vector transfected cells, overexpression of RGS5 inhibited colony formation of both A549 and Calu-3 cells by 46.8 and 52.5%, respectively (Fig. 3D) .
RGS5 induces lung cancer cell apoptosis through activation of the mitochondrial pathway. To explore the possible mechanism responsible for RGS5-mediated cell growth inhibition, cellular apoptosis was evaluated by Annexin V-PI staining and analyzed by flow cytometry. Both A549 and Calu-3 cells have increased populations undergoing apoptosis when transfected with RGS5-expressing plasmid ( Fig. 4A and B) . The proportion of the apoptotic cells untreated, transfected with pTRiEX or pTRiEX-RGS5 at 36 h post-transfection in A549 cells was 1.3±0.2, 3.4±0.6 and 19.6±2.3%, respectively; whereas 3.2±0.8, 3.0±0.9 and 12.8±1.8%, respectively, in Calu-3 cells.
To determine whether caspases were involved in the RGS5-induced apoptosis, we studied the activation of caspase 3 and 9 and the cleavage of PARP. As shown in Fig. 4C, A549 and Calu-3 cells overexpressing RGS5 had decreased levels of pro-caspase 3 and 9, whereas the levels of cleaved form of PARP in the same cell lines were increased, indicating the increased activation of both caspases.
Mitochondria play a critical role in regulating apoptosis. Pro-apoptotic proteins Bax and Bak, as well as anti-apoptotic protein Bcl-2 are involved in regulating the release of mitochondrial protein cytochrome c to initiate the apoptotic cascade. We investigated the effect of RGS5 expression on the levels of Bax, Bak and Bcl-2 proteins. As shown in Fig. 4D , cells transfected with pTRiEX-RGS5 had increased levels of Bax and Bak protein but decreased levels of Bcl-2. Therefore, the ratio of pro-apoptotic/anti-apoptotic was increased when RGS5 was overexpressed in the cells. These results indicated that RGS5 induced apoptosis via mitochondrial pathway in human lung cancer cells.
RGS5 inhibits adhesion and migration of lung cancer cells.
Previous studies have reported that the low level of RGS5 is associated with an increased incidence of lymph node metastasis and more invasion in non-small cell lung cancer patients (21) . Thus, to understand whether RGS5 is responsible for the observed phenotype, we investigated whether the increased levels of RGS5 in human lung cancer cells would inhibit cell adhesion or migration.
Cell adhesion was assessed on the fibronectin-coated surface. A549 and Calu-3 cells were transfected with RGS5 expressing plasmid or vector only control, and were allowed to adhere to the fibronectin-coated surface for 1 h. As shown in Fig. 5A , the overexpression of RGS5 reduced A549 and Calu-3 cell adhesion to fibronectin-coated surfaces by 45.9 and 28.9% respectively, compared to the control cells. The differences were apparent from the microscope images.
Similarly, the effect of RGS5 on cell migration was assessed in the RGS5 expressing A549 and Calu-3 cells. The cells were seeded in the upper chamber, and allowed to migrate through an 8-µm filter. Over a 12-h incubation period, the number of cells penetrated through the filter in vector-and the RGS5-transfected A549 and Calu-3 cells was 39.9±11.2, 10.23±4.42, 44.56±10.6 and 13.08±3.37/field, respectively (Fig. 5B) . To determine the mechanisms of the observation, expression levels of several cell migration markers including Rock1, Rock2, cdc42 and MMP-2 were studied in these cells by western blot analysis. As demonstrated in Fig. 5C , in A549 or Calu-3 cells transfected with pTRiEX-RGS5, the levels of all four proteins were decreased compared to the cells transfected with pTRiEX.
RGS5 enhances the cytotoxic effects of X-ray irradiation on lung cancer cells.
To determine whether increased levels of RGS5 increased the sensitivity of lung cancer cells to radiation, we performed a colony-forming assay with cells expressing higher levels of RGS5 followed by irradiation treatment. The cells transfected with either pTRiEX-RGS5 or pTRiEX were subjected to radiation exposure (2 Gy). Radiation of the cells expressing RGS5 resulted in further inhibition of colony formation ( Fig. 6A and B) . These results suggested that RGS5 enhances the cytotoxic effect of radiation treatment.
To further explore the mechanism of colony formation inhibition after transfection with RGS5 and radiation, the two cell lines were transfected with pTRiEX-RGS5, irradiated at 6 Gy, and then the cell lysates were analyzed by western blot analysis. Combined radiation treatment with RGS5 overexpression led to increased levels of cleaved PARP, cleaved caspase 3 and 9 in both cell types (Fig. 6C) . It is known that radiation treatment would lead to the activation of p53 pathway (24) . We found that phosphorylation of p53 at S15 was increased upon radiation, and was further increased when RGS5 was overexpressed in the radiated cells (Fig. 6C) . As a result, the p53 protein levels were increased in the radiated cells.
Discussion
G-protein-coupled receptors (GPCRs) are a large family of versatile membrane proteins involved in a wide range of physiological processes and pathological diseases (25) . GPCRs classically transmit their signal via the activation of G protein heterotrimer, which exchanges GDP for GTP, dissociates into two parts and is released from the receptors. Both free GTP-bound α subunit and βγ dimers are capable of activating downstream effectors. Signaling is terminated when α subunit hydrolyzes GTP, returns to the GDP-bound state and re-associates with βγ dimers to form inactive heterotrimers (26) . RGS promotes the hydrolysis of GTP, thus, reduces the life span of the active form of α subunit. RGS proteins are emerging as important negative regulators of G-protein-coupled receptor (GPCR) signaling. Growing evidence has demonstrated that RGS proteins are potential drug targets in pathologies including central nervous system diseases, cardiovascular diseases and diabetes. Targeting RGS proteins with small molecule modulators or inhibitors provide specific control or treatment of pathophysiological conditions (27, 28) .
Despite the critical roles GPCRs and G proteins play in tumor and metastasis (29) , studies on the function of RGS protein in cancer cells are still lacking. However, several studies point to the roles of RGS in regulating cancer cell proliferation. Overexpression of RGS3 in HL-60 promoted cell apoptosis (30) . Overexpression of RGS16 inhibited epidermal growth factor (EGF)-induced proliferation and Akt phosphorylation in MCF7 breast cancer cells (31) . Altman et al (32) showed that inducible RGS5 expression significantly reduced proliferation of HeyA8-MDR ovarian cancer cells. Maity et al (33) observed that RGS6 induced breast cancer cell apoptosis.
In the present study, it was demonstrated that overexpression of RGS5 significantly reduced the proliferation of human lung cancer cells by inducing apoptosis. Previous studies have reported that RGS5 is upregulated by hypoxia and overexpression of RGS5 induces apoptosis in HuVECs (34) . It was demonstrated that in human lung cancer cells, the overexpression of RGS5-induced the expressions of pro-apoptotic proteins Bax and Bak; while it reduced the expression of anti-apoptotic protein Bcl-2. Bax, Bak and Bcl-2 are known to be involved in the regulation of the mitochondrial pathway of apoptosis (35) . As a consequence, activation of caspase 3 and 9 was also observed in the RGS5 overexpressing cells.
A previous study indicates an association between the low level of RGS5 and an increased lymph node invasion of the human non-small cell cancer. In addition, RGS4 is found to be involved in reducing breast cancer metastatic abilities in vitro (36, 37) . We found that when overexpressed, RGS5 decreased the adhesion and migration abilities of human lung cancer cells. Accordingly, several cell migration markers including Rock1, Rock2, cdc42 and MMP-2 were downregulated in RGS5 expressing cells (38, 39) . Cancer cell migration is believed to be the initial step in metastasis, in which primary tumor cells migrate and invade neighboring tissues and enter the circulation to establish new or secondary tumor sites during metastasis (40) . Thus, inhibition of cancer cell migration represents one of the potent strategies for cancer treatment. To our knowledge, this is the first demonstration of the impact of RGS5 overexpression on tumor cell migration. Our findings partially explained why lower levels of RGS5 are strongly associated with cancer vascular invasion and lymph node metastasis in NSCLC and indicate RGS5 as a promising target for cancer therapy.
RGS proteins have been shown to modulate the responsiveness of tumor cells to chemotherapeutic agents. The cytotoxic effects of cisplatin, vincristine and docetaxel were reduced following RGS10 and RGS17 knockdown in SKOV-3 as well as MDR-HEYA8 cells (41) . RGS6 was shown to mediate the activation of ATM and p53 by doxorubicin, and genetic loss of RGS6 dramatically impaired doxorubicininduced activation of ATM and p53 in breast cancer cells (42) . Our observation also pointed to a possible role of RGS5 in increasing the sensitivity of the human lung cancer cells to radiation. Colony formation of both cell lines was reduced when RGS5 was overexpressed in the cells, and it was further reduced when these cells were irradiated. Not surprisingly, p53 pathway was activated upon radiation. It is known that p53 promotes apoptosis through modulating the mitochondrial apoptosis pathway. We observed increased levels of cleaved PARP in the RGS5 expressing cells, and they were further increased when the cells were irradiated. We found that RGS5 overexpression led to an increased level of p53, at least in the A549 cells; whereas the effect was less apparent in Calu-3 cells. This may be the explanation for the changes in the levels of pro-apoptotic and anti-apoptotic Bcl-2 proteins in the RGS5 overexpressing cells. Although the exact underlying mechanism of these observations still requires investigation, to our best knowledge, this is the first study on the antitumor effects of RGS protein combined with radiation.
The present study has noticeable limitation in that expression of the RGS5 was transient, which may bring the question of consistency of the transfection rate and the expression level of each experiment. During the study, each experiment was coupled with detection of the RGS5 expression for validation of the data. Our study used an inducible expression system in cancer to further analyze the function of RGS5.
In conclusion, we demonstrated the effects of RGS5 overexpression in growth inhibition, apoptosis and reduction of cell migration in human lung cancer cells. These findings provided evidence that RGS5 played an inhibitory role in human lung cancer cells, which explained the pathoclinical observation that high expression of RGS5 as a favorable prognostic factor in NSCLC patients. Furthermore, RGS5 was shown to enhance the antitumor effects of radiation in human lung cancer cells. Collectively, our results implied that RGS5 may be a promising target for cancer therapy.
